A data-driven interactome of synergistic genes improves network-based cancer outcome prediction

Few-shot genes selection: subset of PAM50 genes for breast cancer subtypes classification

BACKGROUND

In recent years, researchers have made significant strides in understanding the heterogeneity of breast cancer and its various subtypes. However, the wealth of genomic and proteomic data available today necessitates efficient frameworks, instruments, and computational tools for meaningful analysis. Despite its success as a prognostic tool, the PAM50 gene signature's reliance on many genes presents challenges in terms of cost and complexity. Consequently, there is a need for more efficient methods to classify breast cancer subtypes using a reduced gene set accurately.

RESULTS

This study explores the potential of achieving precise breast cancer subtype categorization using a reduced gene set derived from the PAM50 gene signature. By employing a "Few-Shot Genes Selection" method, we randomly select smaller subsets from PAM50 and evaluate their performance using metrics and a linear model, specifically the Support Vector Machine (SVM) classifier. In addition, we aim to assess whether a more compact gene set can maintain performance while simplifying the classification process. Our findings demonstrate that certain reduced gene subsets can perform comparable or superior to the full PAM50 gene signature.

CONCLUSIONS

The identified gene subsets, with 36 genes, have the potential to contribute to the development of more cost-effective and streamlined diagnostic tools in breast cancer research and clinical settings.

AI-Aided Disease Prediction in Visualized Medicine

Artificial intelligence (AI) is playing a vitally important role in promoting the revolution of future technology. Healthcare is one of the promising applications in AI, which covers medical imaging, diagnosis, robotics, disease prediction, pharmacy, health management, and hospital management. Numbers of achievements that made in these fields overturn every aspect in traditional healthcare system. Therefore, to understand the state-of-art AI in healthcare, as well as the chances and obstacles in its development, the applications of AI in disease detection and outlook and the future trends of AI-aided disease prediction were discussed in this chapter.

Data analysis methods for defining biomarkers from omics data

Omics mainly includes genomics, epigenomics, transcriptomics, proteomics and metabolomics. The rapid development of omics technology has opened up new ways to study disease diagnosis and prognosis and to define prospective information of complex diseases. Since omics data are usually large and complex, the method used to analyze the data and to define important information is crucial in omics study. In this review, we focus on advances in biomarker discovery methods based on omics data in the last decade, and categorize them as individual feature analysis, combinatorial feature analysis and network analysis. We also discuss the challenges and perspectives in this field.

A mixture model to detect edges in sparse co-expression graphs with an application for comparing breast cancer subtypes

We develop a method to recover a gene network's structure from co-expression data, measured in terms of normalized Pearson's correlation coefficients between gene pairs. We treat these co-expression measurements as weights in the complete graph in which nodes correspond to genes. To decide which edges exist in the gene network, we fit a three-component mixture model such that the observed weights of 'null edges' follow a normal distribution with mean 0, and the non-null edges follow a mixture of two lognormal distributions, one for positively- and one for negatively-correlated pairs. We show that this so-called L2 N mixture model outperforms other methods in terms of power to detect edges, and it allows to control the false discovery rate. Importantly, our method makes no assumptions about the true network structure. We demonstrate our method, which is implemented in an R package called edgefinder, using a large dataset consisting of expression values of 12,750 genes obtained from 1,616 women. We infer the gene network structure by cancer subtype, and find insightful subtype characteristics. For example, we find thirteen pathways which are enriched in each of the cancer groups but not in the Normal group, with two of the pathways associated with autoimmune diseases and two other with graft rejection. We also find specific characteristics of different breast cancer subtypes. For example, the Luminal A network includes a single, highly connected cluster of genes, which is enriched in the human diseases category, and in the Her2 subtype network we find a distinct, and highly interconnected cluster which is uniquely enriched in drug metabolism pathways.

Prognostic outcome prediction by semi-supervised least squares classification

Although great progress has been made in prognostic outcome prediction, small sample size remains a challenge in obtaining accurate and robust classifiers. We proposed the Rescaled linear square Regression based Least Squares Learning (RRLSL), a jointly developed semi-supervised feature selection and classifier, for predicting prognostic outcome of cancer patients. RRLSL used the least square regression to identify the scale factors and then rank the features in available multiple types of molecular data. We applied the unlabeled multiple molecular data in conjunction with the labeled data to develop a similarity graph. RRLSL produced the constraint with kernel functions to bridge the gap between label information and geometry information from messenger RNA and microRNA expression profiling. Importantly, this semi-supervised model proposed the least squares learning with L2 regularization to develop a semi-supervised classifier. RRLSL suggested the performance improvement in the prognostic outcome prediction and successfully discriminated between the recurrent patients and non-recurrent ones. We also demonstrated that RRLSL improved the accuracy and Area Under the Precision Recall Curve (AUPRC) as compared to the baseline semi-supervised methods. RRLSL is available for a stand-alone software package (https://github.com/ShiMGLab/RRLSL). A short abstract We proposed the Rescaled linear square Regression based Least Squares Learning (RRLSL), a jointly developed semi-supervised feature selection and classifier, for predicting prognostic outcome of cancer patients. RRLSL used the least square regression to identify the scale factors to rank the features in available multiple types of molecular data. RRLSL produced the constraint with kernel functions to bridge the gap between label information and geometry information from messenger RNA and microRNA expression profiling. Importantly, this semi-supervised model proposed the least squares learning with L2 regularization to develop the semi-supervised classifier. RRLSL suggested the performance improvement in the prognostic outcome prediction and successfully discriminated between the recurrent patients and non-recurrent ones.

Network inference in systems biology: recent developments, challenges, and applications

One of the most interesting, difficult, and potentially useful topics in computational biology is the inference of gene regulatory networks (GRNs) from expression data. Although researchers have been working on this topic for more than a decade and much progress has been made, it remains an unsolved problem and even the most sophisticated inference algorithms are far from perfect. In this paper, we review the latest developments in network inference, including state-of-the-art algorithms like PIDC, Phixer, and more. We also discuss unsolved computational challenges, including the optimal combination of algorithms, integration of multiple data sources, and pseudo-temporal ordering of static expression data. Lastly, we discuss some exciting applications of network inference in cancer research, and provide a list of useful software tools for researchers hoping to conduct their own network inference analyses.

ORVAL: a novel platform for the prediction and exploration of disease-causing oligogenic variant combinations

A tremendous amount of DNA sequencing data is being produced around the world with the ambition to capture in more detail the mechanisms underlying human diseases. While numerous bioinformatics tools exist that allow the discovery of causal variants in Mendelian diseases, little to no support is provided to do the same for variant combinations, an essential task for the discovery of the causes of oligogenic diseases. ORVAL (the Oligogenic Resource for Variant AnaLysis), which is presented here, provides an answer to this problem by focusing on generating networks of candidate pathogenic variant combinations in gene pairs, as opposed to isolated variants in unique genes. This online platform integrates innovative machine learning methods for combinatorial variant pathogenicity prediction with visualization techniques, offering several interactive and exploratory tools, such as pathogenic gene and protein interaction networks, a ranking of pathogenic gene pairs, as well as visual mappings of the cellular location and pathway information. ORVAL is the first web-based exploration platform dedicated to identifying networks of candidate pathogenic variant combinations with the sole ambition to help in uncovering oligogenic causes for patients that cannot rely on the classical disease analysis tools. ORVAL is available at https://orval.ibsquare.be.

Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges

Cancer is an aggressive disease with a low median survival rate. Ironically, the treatment process is long and very costly due to its high recurrence and mortality rates. Accurate early diagnosis and prognosis prediction of cancer are essential to enhance the patient's survival rate. Developments in statistics and computer engineering over the years have encouraged many scientists to apply computational methods such as multivariate statistical analysis to analyze the prognosis of the disease, and the accuracy of such analyses is significantly higher than that of empirical predictions. Furthermore, as artificial intelligence (AI), especially machine learning and deep learning, has found popular applications in clinical cancer research in recent years, cancer prediction performance has reached new heights. This article reviews the literature on the application of AI to cancer diagnosis and prognosis, and summarizes its advantages. We explore how AI assists cancer diagnosis and prognosis, specifically with regard to its unprecedented accuracy, which is even higher than that of general statistical applications in oncology. We also demonstrate ways in which these methods are advancing the field. Finally, opportunities and challenges in the clinical implementation of AI are discussed. Hence, this article provides a new perspective on how AI technology can help improve cancer diagnosis and prognosis, and continue improving human health in the future.